AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27903136 — intervention group
Group type: COMPARATOR
Intervention: Minimally enhanced treatment‐as‐usual control condition
Number of subjects: 268
Study 25697576 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80mg/day)
Number of subjects: 120
Study 25697576 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20mg/day)
Number of subjects: 120
Study 24579225 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial occlusive balloons
Number of subjects: 12
Study 24579225 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery (Control)
Number of subjects: 12
Study 21299925 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg methylprednisolone sodium succinate intravenously as a single bolus before surgery
Number of subjects: 42
Study 21299925 — intervention group
Group type: COMPARATOR
Intervention: Control group (no glucocorticoid)
Number of subjects: 42
Study 19484436 — intervention group
Group type: EXPERIMENTAL
Intervention: BioVue 3 HSM hydrophilic acrylic IOL
Number of subjects: 177
Study 19484436 — intervention group
Group type: COMPARATOR
Intervention: Sensar AR40e hydrophobic acrylic IOL
Number of subjects: 177
Study 16730721 — intervention group
Group type: EXPERIMENTAL
Intervention: Single strand conformation polymorphism and sequence analysis for DAZL gene polymorphism screening
Number of subjects: 422
Study 15250791 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive self-stereotypes
Number of subjects: 0
Study 15250791 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative self-stereotypes
Number of subjects: 0
Study 15250791 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental manipulation of group performance expectation
Number of subjects: 0
Study 15250791 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive in-group stereotypes
Number of subjects: 0
Study 15250791 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative stereotypes
Number of subjects: 0
Study 11389862 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoghurt (125 g twice daily for 8 weeks)
Number of subjects: 42
Study 11389862 — intervention group
Group type: COMPARATOR
Intervention: Control (casein‐free soybean ice cream, 125 g twice daily for 8 weeks)
Number of subjects: 42
Study 9269005 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation
Number of subjects: 0
Study 9269005 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 0
Study 8344101 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg post evening meal (pem)
Number of subjects: 1677
Study 8344101 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg nocte
Number of subjects: 1677
Study 8344101 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 800 mg nocte
Number of subjects: 1677
Study 8344101 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg pem
Number of subjects: 1677
Study 3753754 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxyvitamin-D3 (1,25(OH)2D3) therapy (0.25-0.50 microgram/day)
Number of subjects: 10
Study 3753754 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of 1,25(OH)2D3 treatment in five children
Number of subjects: 10
Study 3753754 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute study during 12 HF sessions
Number of subjects: 10
Study 31531828 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative multi-system optimization protocol
Number of subjects: 127
Study 31531828 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 127
Study 30073273 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer comparison letters
Number of subjects: 5055
Study 27118212 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular paracetamol (600 mg)
Number of subjects: 21
Study 27118212 — intervention group
Group type: COMPARATOR
Intervention: Oral syrup paracetamol (600 mg)
Number of subjects: 21
Study 27118212 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular or oral syrup paracetamol (1000 mg administered six-hourly)
Number of subjects: 21
Study 27118212 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose of 1500 mg followed by 1000 mg maintenance dose
Number of subjects: 21
Study 27118212 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol concentrations
Number of subjects: 21
Study 25018116 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD dengue vaccine (three injections at months 0, 6, and 12)
Number of subjects: 10275
Study 25018116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10275
Study 25018116 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD dengue vaccine
Number of subjects: 10275
Study 22198447 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation (N = 269)
Number of subjects: 1292
Study 22198447 — intervention group
Group type: COMPARATOR
Intervention: Switching (N = 269)
Number of subjects: 1292
Study 22198447 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation
Number of subjects: 1292
Study 22198447 — intervention group
Group type: COMPARATOR
Intervention: Switching
Number of subjects: 1292
Study 20085937 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with carboplatin and paclitaxel (PCB) with high blood pressure (HBP)
Number of subjects: 0
Study 20085937 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with carboplatin and paclitaxel (PCB) without high blood pressure (HBP)
Number of subjects: 0
Study 20085937 — intervention group
Group type: COMPARATOR
Intervention: Hypertension incidence
Number of subjects: 0
Study 18574759 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirayama's disease patients in neutral position
Number of subjects: 56
Study 18574759 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirayama's disease patients in flexed position
Number of subjects: 56
Study 18574759 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls in neutral position
Number of subjects: 56
Study 18574759 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls in flexed position
Number of subjects: 56
Study 15983245 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal-proBNP (NT-proBNP)
Number of subjects: 206
Study 15983245 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 206
Study 15983245 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin
Number of subjects: 206
Study 15983245 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP and Renin (both in highest quarters)
Number of subjects: 206
Study 15983245 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP and Renin (after adjustment for other predictors)
Number of subjects: 206
Study 15983245 — intervention group
Group type: COMPARATOR
Intervention: C (Control group)
Number of subjects: 206
Study 12521403 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine 2-mg sublingual tablet (n = 120)
Number of subjects: 241
Study 12521403 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 121)
Number of subjects: 241
Study 10604733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg or 800 mg twice a day)
Number of subjects: 442
Study 10604733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 442
Study 7866815 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg twice daily for 12 weeks, followed by a maximum of four 5 mg tablets (20 mg max daily) for 12 weeks
Number of subjects: 119
Study 7866815 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg twice daily for 6 weeks, then 10 mg for 6 weeks
Number of subjects: 119
Study 1772923 — intervention group
Group type: EXPERIMENTAL
Intervention: HU-PACS (CRT monitor)
Number of subjects: 20
Study 1772923 — intervention group
Group type: COMPARATOR
Intervention: CR film
Number of subjects: 20
Study 6127501 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium toxicity
Number of subjects: 16
Study 6127501 — intervention group
Group type: COMPARATOR
Intervention: Vitamin-D therapy
Number of subjects: 16
Study 6127501 — intervention group
Group type: COMPARATOR
Intervention: Dialysis fluid
Number of subjects: 16
Study 31220015 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional strength and power training
Number of subjects: 30
Study 29101134 — intervention group
Group type: EXPERIMENTAL
Intervention: Steam inhalation for recurrent sinusitis
Number of subjects: 32
Study 29101134 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal irrigation
Number of subjects: 32
Study 27383762 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 5 μg once daily (QD)
Number of subjects: 308
Study 27383762 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 10 μg once daily (QD)
Number of subjects: 308
Study 27383762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study 26030947 — intervention group
Group type: EXPERIMENTAL
Intervention: Translabial three-dimensional sonography (3D USG)
Number of subjects: 100
Study 22822929 — intervention group
Group type: EXPERIMENTAL
Intervention: Johnson's Baby Skincare fragrance free wipe
Number of subjects: 280
Study 22822929 — intervention group
Group type: COMPARATOR
Intervention: Cotton wool and water
Number of subjects: 280
Study 18180760 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotic drugs
Number of subjects: 7323
Study 18180760 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 7323
Study 17855466 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case-managed intervention
Number of subjects: 295
Study 17855466 — intervention group
Group type: COMPARATOR
Intervention: Standard care control program
Number of subjects: 295
Study 15776065 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (specific drug not mentioned)
Number of subjects: 0
Study 15776065 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (not specified)
Number of subjects: 0
Study 11957789 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidative therapy
Number of subjects: 0
Study 11957789 — intervention group
Group type: COMPARATOR
Intervention: Antioxidative vitamins (tocopherol)
Number of subjects: 0
Study 10335929 — intervention group
Group type: EXPERIMENTAL
Intervention: Italian version of the Hospital Anxiety and Depression Scale (HADS) administered before chemotherapy and at follow-up.
Number of subjects: 197
Study 10335929 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operating characteristics (ROC) analysis for HADS.
Number of subjects: 197
Study 10335929 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-item total scale of HADS.
Number of subjects: 197
Study 8635777 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (PN) with amino acid based glucose electrolyte solution (Vamin) and lipid emulsion (Intralipid)
Number of subjects: 85
Study 8635777 — intervention group
Group type: COMPARATOR
Intervention: Conventional intravenous dextrose with or without electrolytes plus enteral milk regimen
Number of subjects: 85
Study 2035442 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (4 mg)
Number of subjects: 12
Study 2035442 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (10 mg)
Number of subjects: 12
Study 7044535 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmustine (BCNU), cyclophosphamide, and prednisone (BCP)
Number of subjects: 0
Study 7044535 — intervention group
Group type: COMPARATOR
Intervention: Melphalan (Alkeran) and prednisone (AP)
Number of subjects: 0
Study 29288402 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive prevention in kindergarten with fluoride gel at school
Number of subjects: 0
Study 29288402 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive prevention in kindergarten without fluoride gel at school
Number of subjects: 0
Study 29288402 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic prevention in kindergarten with fluoride gel at school
Number of subjects: 0
Study 29288402 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic prevention in kindergarten without fluoride gel at school
Number of subjects: 0
Study 29288402 — intervention group
Group type: EXPERIMENTAL
Intervention: No organized prevention in kindergarten with fluoride gel at school
Number of subjects: 0
Study 29288402 — intervention group
Group type: EXPERIMENTAL
Intervention: No organized prevention in kindergarten without fluoride gel at school
Number of subjects: 0
Study 27859680 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching Recovery Techniques (TRT) intervention
Number of subjects: 482
Study 27859680 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 482
Study 27859680 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 482
Study 25047245 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Solving Treatment
Number of subjects: 120
Study 25047245 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 120
Study 22849403 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased activation in the right pars triangularis during fMRI tasks in older adults
Number of subjects: 0
Study 22849403 — intervention group
Group type: EXPERIMENTAL
Intervention: Right pars orbitalis activation during the word task in older adults
Number of subjects: 0
Study 22849403 — intervention group
Group type: COMPARATOR
Intervention: Behavioral performance in fMRI task
Number of subjects: 0
Study 19615826 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized E(2) 1mg/day
Number of subjects: 25
Study 19615826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 18685050 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet gel
Number of subjects: 35
Study 18685050 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 35
Study 16794387 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (LNF)
Number of subjects: 177
Study 16794387 — intervention group
Group type: COMPARATOR
Intervention: Conventional Nissen fundoplication (CNF)
Number of subjects: 177
Study 12571296 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 514
Study 12571296 — intervention group
Group type: COMPARATOR
Intervention: Nonresurfacing of the patella
Number of subjects: 514
Study 12571296 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary resurfacing
Number of subjects: 514
Study 12571296 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral knee replacement with resurfacing
Number of subjects: 514
Study 11070746 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast ('Accolate') 20 mg twice daily
Number of subjects: 60
Study 8889482 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotonic glucose‐electrolyte solution (H: 90 mmol/l glucose; 60 mmol/l Na+; 240 mosmol/kg)
Number of subjects: 12
Study 8889482 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic glucose‐electrolyte solution (I: 200 mmol/l glucose; 35 mmol/l Na+; 310 mosmol/kg)
Number of subjects: 12
Study 8889482 — intervention group
Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 12
Study 8889482 — intervention group
Group type: COMPARATOR
Intervention: No drink
Number of subjects: 12
Study 8889482 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotonic glucose‐electrolyte solution (H)
Number of subjects: 12
Study 8889482 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 12
Study 1987957 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Doppler ultrasound monitoring of blood velocity in the fetal aorta and umbilical artery
Number of subjects: 139
Study 1987957 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical artery examination
Number of subjects: 139
Study 6297202 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids (dexamethasone 2.0 mg/day for 3 days)
Number of subjects: 6
Study 6297202 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of glucocorticoid substitution therapy for 84 hours
Number of subjects: 6
Study 6297202 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous ACTH1-24 administration
Number of subjects: 6
Study 30842160 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (RT)
Number of subjects: 86
Study 30842160 — intervention group
Group type: COMPARATOR
Intervention: Patients with breast cancer
Number of subjects: 86
Study 30842160 — intervention group
Group type: COMPARATOR
Intervention: Healthy female blood donors (control cohort)
Number of subjects: 86
Study 28438238 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 42
Study 28438238 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Number of subjects: 42
Study 28438238 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 42
Study 25730788 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranoff (Test drug) 500mg, two capsules, prescribed for 2-3 weeks
Number of subjects: 130
Study 25730788 — intervention group
Group type: COMPARATOR
Intervention: Urixin (Control drug) 400mg capsules, prescribed for 2-3 weeks
Number of subjects: 130
Study 25730788 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranoff (Test drug)
Number of subjects: 130
Study 23749615 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupation-related rehabilitation program (IG)
Number of subjects: 309
Study 23749615 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 309
Study 21087403 — intervention group
Group type: EXPERIMENTAL
Intervention: NGX-4010 (8% capsaicin dermal patch, 640 µg/cm²)
Number of subjects: 418
Study 21087403 — intervention group
Group type: COMPARATOR
Intervention: 0.04% capsaicin control patch (3.2 µg/cm²)
Number of subjects: 418
Study 20029098 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance-training group (5-kg medicine ball, 2 sets of 8 reps per session)
Number of subjects: 64
Study 20029098 — intervention group
Group type: EXPERIMENTAL
Intervention: Velocity-training group (regular soccer ball, 4 sets of 16 reps per session)
Number of subjects: 64
Study 20029098 — intervention group
Group type: COMPARATOR
Intervention: Control group (5-kg medicine ball)
Number of subjects: 64
Study 17161760 — intervention group
Group type: EXPERIMENTAL
Intervention: PREHAB - individualized program focusing on impairments (standardly tailored design)
Number of subjects: 366
Study 17161760 — intervention group
Group type: EXPERIMENTAL
Intervention: DRIVER - entire intervention (global design)
Number of subjects: 366
Study 14748023 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with x 2.5 magnification and microsurgical instruments (Group A)
Number of subjects: 97
Study 14748023 — intervention group
Group type: COMPARATOR
Intervention: Surgery with no magnification (Group B)
Number of subjects: 97
Study 11577259 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban/heparin
Number of subjects: 110
Study 11577259 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 110
Study 9570601 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia Block (SAB)
Number of subjects: 39
Study 9570601 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Sciatic and Femoral Block (SFB)
Number of subjects: 39
Study 7804511 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 49
Study 7804511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 3392220 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of worry
Number of subjects: 128
Study 3392220 — intervention group
Group type: COMPARATOR
Intervention: Other conditions (depressed, somatically anxious, neutral)
Number of subjects: 128
Study 31471115 — intervention group
Group type: EXPERIMENTAL
Intervention: Milking of umbilical cord blood
Number of subjects: 0
Study 31471115 — intervention group
Group type: COMPARATOR
Intervention: Delayed clamping of umbilical cord blood
Number of subjects: 0
Study 31036040 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRA + oxaliplatin + 5-fluorouracil/leucovorin (FOLFOX4)
Number of subjects: 368
Study 31036040 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX4 alone
Number of subjects: 368
Study 28623938 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone administration
Number of subjects: 32
Study 28623938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 26041459 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet and increased walking
Number of subjects: 40
Study 26041459 — intervention group
Group type: COMPARATOR
Intervention: American Diabetes Association diet
Number of subjects: 40
Study 22963833 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy for 24-38 weeks
Number of subjects: 527
Study 22963833 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 527
Study 21045817 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemp Seed Pill (HSP) 7.5 g b.i.d.
Number of subjects: 120
Study 21045817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 19661478 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychosocial-behavioral intervention plus antidepressant
Number of subjects: 101
Study 19661478 — intervention group
Group type: COMPARATOR
Intervention: Usual care including antidepressant
Number of subjects: 101
Study 16707901 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 89
Study 16707901 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape obturator (TVT-O)
Number of subjects: 89
Study 15114207 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml/kg NaCl, 7.5%
Number of subjects: 62
Study 15114207 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml/kg NaCl, 0.9%
Number of subjects: 62
Study 15114207 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 ml/kg NaCl, 0.9%
Number of subjects: 62
Study 15114207 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 62
Study 11556267 — intervention group
Group type: EXPERIMENTAL
Intervention: Pen-switching method
Number of subjects: 100
Study 11556267 — intervention group
Group type: COMPARATOR
Intervention: Flowchart method
Number of subjects: 100
Study 9631218 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise challenge test (ECT) in subzero temperature during winter
Number of subjects: 58